RNXT RenovoRx, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1574094 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-17.2%
TTM EPS YoY13.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin84.0%
Operating margin-489.0%
Net margin-469.0%
FCF margin-440.4%
EBITDA margin-416.6%
Returns
ROE-150.0%
ROA-110.1%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets25.4%
Debt / equity0.00x
Current ratio5.65x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue3.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.07M | $909,000 | $563,000 | $238,000 | $266,000 | $422,000 | $197,000 | — |
| Cost of revenue | $188,000 | $143,000 | $84,000 | $28,000 | $53,000 | $152,000 | $94,000 | — |
| Gross profit | $878,000 | $766,000 | $479,000 | $210,000 | $213,000 | $270,000 | $103,000 | — |
| R&D expense | $1.24M | $1.20M | $1.23M | $1.50M | $1.69M | $1.43M | $1.64M | $1.58M |
| SG&A expense | $2.87M | $2.92M | $2.72M | $2.23M | $1.73M | $1.52M | $1.57M | $1.10M |
| Operating income | -$3.24M | -$3.35M | -$3.47M | -$3.52M | -$3.20M | -$2.68M | -$3.11M | -$2.63M |
| Income tax | $0 | $0 | $0 | $2,000 | $0 | $0 | $0 | — |
| Net income | -$3.65M | -$2.91M | -$3.52M | -$2.94M | -$2.91M | -$2.90M | -$2.42M | -$2.88M |
| EBITDA | -$3.23M | -$3.34M | -$3.47M | -$1.52M | -$2.20M | -$1.68M | -$3.11M | — |
| EPS (basic) | -0.08 | -0.06 | -0.09 | — | -0.08 | -0.08 | -0.08 | — |
| EPS (diluted) | -0.08 | -0.06 | -0.09 | — | -0.08 | -0.08 | -0.08 | — |
| Weighted avg. shares (diluted) | 48.19M | 47.30M | 38.03M | — | 36.65M | 36.58M | 31.40M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $10.40M | $9.48M | $12.36M | $7.02M | $10.04M | $12.31M | $14.58M | $7.15M |
| Receivables | $609,000 | $480,000 | $280,000 | $139,000 | $169,000 | $363,000 | $242,000 | $43,000 |
| Inventory | $341,000 | $383,000 | $379,000 | $189,000 | $272,000 | — | — | $0 |
| Current assets | $11.81M | $10.81M | $13.72M | $7.89M | $10.98M | $13.39M | $15.74M | $7.83M |
| PP&E, net | $89,000 | $94,000 | $77,000 | $12,000 | $13,000 | $13,000 | $13,000 | $12,000 |
| Total assets | $12.44M | $11.47M | $13.96M | $8.10M | $11.21M | $13.64M | $16.01M | $8.12M |
| Current liabilities | $2.09M | $1.88M | $1.92M | $1.96M | $1.88M | $1.56M | $1.74M | $1.91M |
| Total liabilities | $3.15M | $2.49M | $2.70M | $2.67M | $3.13M | $3.00M | $2.86M | $3.64M |
| Shareholders' equity | $9.28M | $8.98M | $11.27M | $5.42M | $8.08M | $10.64M | $13.16M | $4.48M |
| Shares outstanding | 48.19M | 45.12M | 45.05M | 36.61M | 36.65M | 36.65M | 36.55M | 24.03M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.54M | -$2.87M | -$3.71M | -$3.02M | -$2.27M | -$2.30M | -$3.38M | -$2.43M |
| Capital expenditure | $19,000 | $71,000 | $0 | $0 | $0 | $0 | $2,000 | — |
| Free cash flow | -$2.56M | -$2.94M | -$3.71M | -$3.02M | -$2.27M | -$2.30M | -$3.38M | — |
| Investing cash flow | -$19,000 | -$71,000 | $0 | $0 | $0 | $0 | -$2,000 | — |
| Financing cash flow | $3.48M | $55,000 | $9.05M | $0 | $0 | $34,000 | $10.81M | $33,000 |
| Depreciation & amortization | $5,000 | $5,000 | $1,000 | $2.00M | $1.00M | $1.00M | $1,000 | — |
| Stock-based compensation | $469,000 | $570,000 | $317,000 | $285,000 | $349,000 | $345,000 | $288,000 | $252,000 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.